Dicerna Pharmaceuticals Inc

Dicerna Pharmaceuticals — Technical Presentation (August 2020)

83 slides from Dicerna Pharmaceuticals's technical presentation, Aug 6, 2020

  1. Slide 1: Dicerna 2020 Virtual R&D Update: Nedosiran, RG6346 and Going Beyond GalXC

    Dicerna 2020 Virtual R&D Update: Nedosiran, RG6346 and Going Beyond GalXC™ August 6, 2020 Exhibit 99.3

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Examples of forward-looking statements inc

  3. Slide 3: Today's Speakers

    Today’s Speakers Man-Fung Yuen, M.D., Ph.D. Chair Professor and Endowed Professor in Medicine of the Li Shu Fan Medical Foundation, University of Hong Kong Douglas M. Fambrough, Ph.D. President and Chief Executive Officer Dicerna Pharmaceuticals Bob D. Brown, Ph.D. Chief Scientific Officer, Executiv

  4. Slide 4: Program Agenda

    Program Agenda Corporate Vision and Strategy Douglas M. Fambrough, Ph.D. 10:00 – 10:10 a.m. RG6346 Phase 1 Data and Next Steps Bob D. Brown, Ph.D. Man-Fung Yuen, M.D., Ph.D. 10:10 – 10:50 a.m. Q&A All Presenters 10:50 – 11:00 a.m. Nedosiran PHYOX™3 Data and Commercial Planning Bernd Hoppe, M.D. Ralf

  5. Slide 5: Vision and Strategy

    Vision and Strategy Douglas M. Fambrough, Ph.D., President and Chief Executive Officer

  6. Slide 6: Vision and Strategy

    VISION Develop and commercialize our core high-probability-of-success programs either alone or in collaboration with partners Broadly enable the use of our GalXC technology by collaborating with therapeutic area leaders on non-core opportunities STRATEGY Maximize the impact of RNAi on medicine

  7. Slide 7: The RNAi Modality Has Come of Age

    Established safety in large population studies Multiple committed large pharmas Approved Products Multiple candidates in registration or pivotal development The RNAi Modality Has Come of Age Liver targets formed the foundation for RNAi’s early success. Today, RNAi technologies are exploring the vast

  8. Slide 8: Expansive Opportunity for RNAi Throughout the Body

    Expansive Opportunity for RNAi Throughout the Body Proprietary extended Dicerna structure provides unparalleled medicinal chemistry flexibility CNS collaboration with Lilly with multiple ongoing discovery programs Subcutaneous delivery for muscle and adipose tissue will be presented today Additional

  9. Slide 9: Core Pipeline Candidates

    CANDIDATE / TARGET INDICATION DISCOVERY/ RESEARCH PRECLINICAL CLINICAL PROOF-OF-CONCEPT TRIALS REGISTRATION TRIALS DICERNA’S PRODUCT RIGHTS Nedosiran Primary Hyperoxaluria Types 1, 2, 3 100% RG6346 Hepatitis B Virus U.S. opt-in* DCR-A1AT ALN-AAT02 A1AT Liver Disease 100% U.S. Alnylam ex-U.S. opt-in

  10. Slide 10: Best-In-Class Opportunities

    We Believe Dicerna Is Creating Best-In-Class Opportunities In Hepatitis B Dicerna’s X-sparing approach drives extended duration of effect that may lead to treatments that are both more convenient and more effective that non-X-sparing approaches In Primary Hyperoxaluria Dicerna conducted fundamental

  11. Slide 11: Deep Collaboration Pipeline

    Deep Collaboration Pipeline Over 15 Preclinical Targets In Process Across Multiple Therapeutic Categories Liver-Related Cardiometabolic Diseases Chronic HBV LY3561774 LY3819469 DCR-CM4 DCR-CM5 DCR-NEURO1 DCR-NEURO2 DCR-LLY9 DCR-PAIN1 DCR-PAIN2 DCR-LLY10 Cardiometabolic, Neurodegeneration, Pain, Undi

  12. Slide 12: Successfully Executing on High-Value Collaboration Strategy

    $175M upfront $75M total annuals $50M equity $200M upfront $100M upfront $100M equity 1 NASH Target $5M option exercised $10M upfront $22M upfront $15M equity Successfully Executing on High-Value Collaboration Strategy Nov. 2017 Oct. 2018 Oct. 2018 Oct. 2019 Nov. 2019 signed Dicerna retains opt-in r

  13. Slide 13: HBsAg Reduction: The X-Sparing Hypothesis

    HBV HBsAg Reduction: The X-Sparing Hypothesis Bob D. Brown, Ph.D. Chief Scientific Officer, Executive Vice President Research & Development

  14. Slide 14: Hepatitis B: A Severe, Global Unmet Medical Need

    Hepatitis B: A Severe, Global Unmet Medical Need Significant worldwide prevalence: ~292 million infected Causes more than 887,000 deaths per year Current treatments are rarely effective in achieving functional cures Dicerna is collaborating with Roche to develop RG6346 and potentially other agents f

  15. Slide 15: The Promise of RNAi for the Treatment of Chronic HBV

    The Promise of RNAi for the Treatment of Chronic HBV Organization of the HBV Genome Enables Effective RNAi Targeting of Multiple Viral Functions AAAAA P gene Polymerase. Involved in viral genome production S gene (HBsAg) Surface protein. Involved in viral coat and immune tolerizing agent X gene Invo

  16. Slide 16: Superior HBsAg Reduction When Targeting Only the Conserved S Region

    Superior HBsAg Reduction When Targeting Only the Conserved S Region Conserved S Region only: ≥3.9 log reduction, long duration of activity Conserved S & X Regions: 3.0 log reduction, shorter duration of activity Striking Differences Between Targeting S Region Alone vs. S and X Regions in a Preclinic

  17. Slide 17: Known X Gene Function Supports Role as an S Gene Regulator

    Known X Gene Function Supports Role as an S Gene Regulator Leaving X Gene Function Intact is Predicted to Give Better HBsAg Suppression Immunohistochemical staining of mouse liver sections for HBV Core protein reveals differential subcellular localization in the HDI-HBV plasmid model Silencing of X

  18. Slide 18: Phase 1 Trial: RG6346 for the Treatment of HBV Infection

    Phase 1 Trial: RG6346 for the Treatment of Hepatitis B Virus (HBV) Infection Man-Fung Yuen, D.Sc., M.D., Ph.D. Chair Professor & Endowed Professor in Medicine, Li Shu Fan Medical Foundation; Chief of the Division of Gastroenterology & Hepatology and Deputy Head of the Department of Medicine, Queen M

  19. Slide 19: Man-Fung Yuen, D.Sc., M.D., Ph.D.

    Man-Fung Yuen, D.Sc., M.D., Ph.D. A therapeutic expert and pioneering clinical researcher leading numerous studies on novel antiviral and immunomodulatory agents for the treatment of chronic hepatitis B virus infection Research includes prevention, natural history, molecular virology, treatment of c

  20. Slide 20: Disclosures

    Disclosures Dr. Yuen is currently a principal investigator for Dicerna’s HBVS-101 study and was a member of our clinical advisory board that was held in 2019. Dr. Yuen has received compensation from Dicerna for both these activities. His role as an investigator in the HBVS-101 study and as a member

  21. Slide 21: Global Impact: Still Increasing HBV Disease Mortality

    Global Impact: Still Increasing HBV Disease Mortality Unlike HIV, tuberculosis, and malaria, mortality from viral hepatitis is increasing Putting it into context: mortality from HBV-related diseases each year is higher than current worldwide mortality from COVID-19 Source: WHO Global Health Estimate

  22. Slide 22: HBsAg Clearance Remains Key to Chronic Hepatitis B Treatment Paradigm

    Present Treatment Aims/Goals The new treatment paradigm is to continue CHB treatment until HBsAg seroclearance is achieved for both HBeAg-positive and HBeAg-negative CHB patients, potentially resulting in functional cure Treatment guidelines from APASL, EASL and AASLD all agree that this is the opti

  23. Slide 23: Key Study Inclusion/Exclusion Criteria and Design

    Key Study Inclusion/Exclusion Criteria: HBeAg positive with HBsAg >1000 IU/mL or HBeAg negative with HBsAg >500 IU/mL; NUC naïve with screening serum HBV DNA >2000 IU/mL and ALT ≥35 U/L (males) or ≥30 U/L (females) Clinical history compatible with compensated liver disease, with no evidence of cirrh

  24. Slide 24: Patient Baseline Characteristics Well Balanced Across Cohorts

    Patient Baseline Characteristics Well Balanced Across Cohorts COHORT C COHORT B 1.5 mg/kg (N=4) 3 mg/kg (N=4) 6 mg/kg (N=4) C (Placebo) (N=6) Total C Cohorts (N=18) 3 mg/kg (N=6) B (Placebo) (N=3) Total B Cohort (N=9) Age at Screening (years) Mean (SD) 37.8 (6.7) 46.5 (5.8) 51.8 (12.5) 45.2 (6.2) 45

  25. Slide 25: RG6346 Showed Strong, Durable Reduction in HBsAg Levels at All Doses

    At Day 112 (end of treatment), mean HBsAg log10 IU/mL reduction from baseline in Group C was: 1.39 (SD 0.38) for 1.5 mg/kg cohort 1.80 (SD 0.57) for 3 mg/kg cohort 1.84 (SD 0.79) for 6 mg/kg cohort Mean max. HBsAg log10 IU/mL reduction was 1.88 (SD 0.52) for 3 mg/kg cohort; 1.84 (SD 0.79) for 6 mg/k

  26. Slide 26: Interim Results: Maximum HBsAg Change From Baseline for Group C

    Interim Results: Maximum HBsAg Change From Baseline for all Group C Participants Who Reached at Least Day 112 Data reflect participants who have completed the treatment period, i.e., Day 112 No Significant Difference in Max. HBsAg Change From Baseline for HBeAg+ vs. HBeAg- Participants 80% of subjec

  27. Slide 27: RG6346 Led to Reduction in HBV-DNA in NUC-Experienced Patient

    RG6346 Led to Reduction in HBV-DNA in NUC-Experienced Patient With Previously Incomplete Response Patient Experienced Drop to Levels Below the Limit of Quantification When RG6346 Added HBeAg+ Patient on NUC Therapy Had Persistent HBV-DNA Until RG6346 Initiated Results shown as of June 25, 2020 data

  28. Slide 28: Reductions in Key Viral Markers Across All Group C Dose Levels

    Treatment With RG6346 + NUCs Resulted in Reductions in Key Viral Markers Across All Group C Dose Levels Mean HBcrAg Reductions Mean HBeAg Reductions Days Conditional Follow-Up Conditional Follow-Up Days HBeAg: minimum n=2 for each dose cohort; full data not collected for 1.5 mg/kg cohort HBrcAg: 1.5

  29. Slide 29: Two Additional Group B NUC-Naïve Patients Had Similar Responses

    Two Additional Group B NUC-Naïve Patients Had Similar Responses Patient from Group B, 3 mg/kg cohort NUC-Naïve Patient With Transient ALT Elevation and Overall Preserved Liver Function Suggests Flare With Enhanced Host Immune Response Synthetic and Excretory Liver Function Preserved ALT Elevation As

  30. Slide 30: NUC-Naïve Patient With Transient ALT Elevation

    NUC-Naïve Patient With Transient ALT Elevation and Overall Preserved Liver Function Suggests Flare With Enhanced Host Immune Response Relationship of ALT Flare and Reduction in HBsAg and HBV-DNA Days ALT Elevation Coincides With Decline in HBV-DNA and HBsAg Reduction

  31. Slide 31: NUC-Experienced Patient Had Mild Serum ALT Elevation

    NUC-Experienced Patient Had Mild Serum ALT Elevation Associated With 2.5 Log10 IU/mL HBsAg Reduction Patient’s ALT Elevation Also Associated With Preserved Liver Synthetic and Excretory Function Days Synthetic and Excretory Liver Function Preserved All HBV-DNA and HBV-RNA values, at all time points,

  32. Slide 32: RG6346 Appeared Safe and Generally Well Tolerated

    In the Phase 1 Patients, RG6346 Appeared To Be Safe and Generally Well Tolerated as of the Interim Analysis No serious adverse events (SAEs) associated with RG6346 observed as of June 25, 2020 in Groups B or C One participant in Group A (healthy volunteer on placebo) experienced one SAE not related

  33. Slide 33: RG6346 Generally Well Tolerated With Four Monthly Doses

    Preliminary Data Demonstrates RG6346 Was Generally Well Tolerated With Four Monthly Doses COHORT C COHORT B 1.5 mg/kg (N=4) 3 mg/kg (N=4) 6 mg/kg (N=4) C (Placebo) (N=6) Total C Cohorts (N=18) 3 mg/kg (N=6) B (Placebo) (N=3) Total B Cohort (N=9) Number of participants with at least 1 possibly-relate

  34. Slide 34: RG6346 Phase 1 Trial Interim Analysis Summary

    RG6346 Phase 1 Trial Interim Analysis Summary Participants treated with RG6346 and concomitant NUC therapy had meaningful and sustained reductions in HBsAg for all dose levels at end of treatment period 80% of subjects on active treatment had >1.5 log10 IU/mL reduction In the 3 mg/kg and 6 mg/kg coh

  35. Slide 35: RG6346 Phase 1: Encouraging HBsAg Reduction and Duration of Response

    RG6346 Phase 1: Encouraging HBsAg Reduction and Duration of Response Phase 1 proof-of-concept study confirms X-sparing hypothesis and potential for best-in-class activity Innovative and thoughtfully designed development strategy provided additional insight to RG6346 effect HBsAg reduction and long d

  36. Slide 36: Our Investigators & Site Teams

    Our Investigators & Site Teams Dr. Edward Gane Dr. Jung-Hwan Yoon Dr. Man-Fung Yuen Dr. Pisit Tangkijvanich Dr. Alexander Thompson Dr. Tien Huey Lim Dr. Wattana Sukeepaisarnjaroen Dr. Won Kim Dr. William Sievert Our Partners Innocent Clement Hardean Achneck Mark Pirner Wendy Cyr Jeremy Cronin Andrew

  37. Slide 37: HBV Q&A

    HBV Q&A All Presenters

  38. Slide 38: Primary Hyperoxaluria: Unmet Need and Treatment Paradigm

    Primary Hyperoxaluria: Unmet Need and Treatment Paradigm Bernd Hoppe, M.D. Vice President, Global Medical Affairs, Head of the German Hyperoxaluria Center and Professor of Pediatrics at University of Cologne

  39. Slide 39: PH: A Family of Rare Disorders Causing Hepatic Oxalate Overproduction

    PH: A Family of Rare Disorders Causing Hepatic Oxalate Overproduction Resulting in Life-Threatening Kidney Damage In all PH subtypes, LDH is Believed to Catalyze the Conversion of Glyoxylate to Oxalate Renal damage is caused by Calcium Oxalate crystals that primarily lead to nephrolithiasis and/or n

  40. Slide 40: PH Is More Common Than Previously Thought

    PH Is More Common Than Previously Thought, Affecting an Estimated 8,500 People in the U.S. Expected U.S. prevalence from genetic studies1,2: 1:58,000 or ~8,500 people >80% of patients currently undiagnosed1 Expected Prevalence* PH1 ~2,700 PH2 ~1,700 PH3 ~4,100 Expected Ratio* Approximately 11% of pa

  41. Slide 41: Kidney Stones Are a Hallmark of All PH Subtypes

    Abbreviation: CaOx, calcium oxalate. 1. Milliner DS, et al. Kidney Int. 2001;59(1):31-36. 2. Soliman NA, et al. Nephrol Ther. 2017;13(3):176-182. 3. Takayama T, et al. Clin Genet. 2014;86(4):342-348. 4. Johnson SA, et al. Pediatr Nephrol. 2002;17(8):597-601. 5. Garrelfs SF, et al. Kidney Int. 2019;9

  42. Slide 42: A Single Kidney Stone in Children and Recurrent Stones in Adults Can Be Signs of PH

    A Single Kidney Stone in Children and Recurrent Stones in Adults Can Be Signs of PH Warning signs can include one or a combination of the following symptoms1-11: Family history of kidney or bladder stones CKD with no known etiology Recurrent UTIs, flank pain, hematuria Severe infantile form: Failure

  43. Slide 43: PH Often Has Early Onset, But Symptom Timing Varies

    Abbreviations: CKD, chronic kidney disease; ESRD, end-stage renal disease. *Limited data, N=4 patients. 1. Hopp K, et al. J Am Soc Nephrol. 2015;26(10):2559-2570. 2. Mandrile G, et al. Kidney Int. 2014;86(6):1197-1204. 3. Garrelfs SF. Kidney Int. 2019;96(6):1389-1399. 4. Allard L, et al. Pediatr Nep

  44. Slide 44: Renal Damage Caused by Oxalate May Not Be Reversible

    Abbreviations: CaOx, calcium oxalate; ESRD, end-stage renal disease. *Case courtesy of Dr Ian Bickle, Radiopaedia.org, rID: 45927. 1. Lai C, et al. Mol Ther. 2018;26(8):1983-1995. 2. Harambat J, et al. Int J Nephrol. 2011;2011:864580. 3. Cochat P, Rumsby G. N Engl J Med. 2013;369(7):649-658. 4. Sali

  45. Slide 45: Earlier Diagnosis Is Needed to Improve Patient Outcomes

    Multiple Studies Show That Earlier Diagnosis Is Needed to Improve Patient Outcomes and Preserve Renal Function A separate study found that3 ~5% are diagnosed after kidney transplant 19% of those diagnosed after transplant are not diagnosed until after first transplant failure of patients with PH exp

  46. Slide 46: Current Treatments for PH Do Not Stop Disease Progression

    Current Treatments for PH Do Not Stop Disease Progression and Can Contribute to Patient Burden Kidney Stone Management1-4 Percutaneous nephrolithotomy (PCNL) or ureteroscopy Renal Replacement Therapy1 Intermittent hemodialysis (HD), additional peritoneal dialysis (PD) in some patients Organ Transpla

  47. Slide 47: Nedosiran for the Treatment of Primary Hyperoxaluria

    Nedosiran for the Treatment of Primary Hyperoxaluria Ralf Rosskamp, M.D. Chief Medical Officer

  48. Slide 48: Nedosiran Is Designed to Inhibit the Final Common Step in Oxalate Production

    Nedosiran Is Designed to Inhibit the Final Common Step in Oxalate Production GO = glycolate oxidase LDHA = lactate dehydrogenase A Kidney function preservation Kidney stones Impacted by ESRD and systemic oxalosis Targeting GO blocks glyoxylate in PH1 only Known Types of Primary Hyperoxaluria PH1 Gen

  49. Slide 49: Human Genetic Deficiency Supports Safety of Liver LDHA Inhibition

    Human Genetic Deficiency Supports Safety of Liver LDHA Inhibition LDHA is involved in the inter-conversion of lactate to pyruvate Human data in PHYOX1 in HVs up to 12mg/kg of nedosiran show no changes in plasma lactate and pyruvate concentrations over placebo Preclinical studies of nedosiran in mice

  50. Slide 50: Final Results From PHYOX1 Single-Dose Phase 1 Study

    Final Results From PHYOX1 Single-Dose Phase 1 Study of Nedosiran in Participants With PH1 or PH2 PHYOX1: Mean Urinary Oxalate Levels by Dose* PH Type Dose (mg/kg) Pts. Reaching Normalization or Near-Normalization (%) Max Reduction Uox (%) Mean (range) PH1 1.5 (n=5) 3 (60) 51 (28-72) 3.0 (n=6) 5 (83)

  51. Slide 51: Monthly Dosing is a Simple Choice for Participants

    1Cowan R et al. Physician and patient preferences for dosing options in migraine prevention. J Headache Pain 20, 50 (2019). Monthly Dosing is a Simple Choice for Participants and May Safeguard Against Sudden Oxalate Spikes Consistency - Based on modeling and simulation of PK and PD data from the PHY

  52. Slide 52: PHYOX3 Clinical Trial Design

    PHYOX3 Clinical Trial Design 3-Year Open-Label Extension Study for Participants With PH1, PH2 or PH3 From Another PHYOX Study Key evaluation objectives: Effect on estimated glomerular filtration rate (eGFR) Effect on new stone formation and nephrocalcinosis Effect on Uox levels Safety and tolerabili

  53. Slide 53: Demographics and Baseline Uox Values for PHYOX3

    Demographics and Baseline Uox Values for PHYOX3 Data Reflect 11 Participants Who Rolled Over From PHYOX1 and Have Reached Day 120 (5 Doses) PHYOX3 BSA corrected baseline values are lower compared to PHYOX1 BSA corrected baseline values Average 0.926 mmol/1.73m2 BSA/24hr for PHYOX3, versus 1.323 mmol

  54. Slide 54: PHYOX3 BSA Corrected Mean 24-Hour Uox Absolute Values

    PHYOX3 BSA Corrected Mean 24-Hour Uox Absolute Values for Participants With 5 Doses of 170 mg of Nedosiran Day 120 BSA corrected mean value for all participants (n=11): 0.524 mmol/1.73m2 BSA/24hr 24 hr Urinary Oxalate Corrected for BSA (mmol/1.73m2 BSA/24hr) Mean±SEM 2.0 2.5 1.0 1.5 0.0 0.5 BL (101)

  55. Slide 55: PHYOX3 Mean Percent Reduction of Uox Values

    PHYOX3 Mean Percent Reduction of Uox Values for Participants With 5 Doses of 170 mg of Nedosiran Mean Reduction From PHYOX1 Pre-Treatment Baseline Day 120 mean reduction value for all participants (n=11): 54.3% Mean % reduction in urinary oxalate from baseline (±SEM) 0 20 -40 -20 -100 -60 0 30 60 90

  56. Slide 56: Normalization and Near-Normalization of Uox Levels

    Normalization and Near-Normalization of Uox Levels As of interim analysis, five participants have reached normal Uox concentrations at 3 consecutive visits and are eligible for weaning off disease management, including hyperhydration For PH1 participants, the average Uox level achieved is in the nor

  57. Slide 57: Similarities and Differences Between PHYOX3 and PHYOX2

    Similarities and Differences Between PHYOX3 Open-Label Extension Study and PHYOX2 Pivotal Registration Study Patient Population PH1 and PH2 participants Ages 6 and above PH1, PH2 and PH3 participants PHYOX1 rollover participants are 12 and above, younger ages may enroll from other trials; siblings o

  58. Slide 58: PHYOX3 Interim Safety Data

    PHYOX3 Interim Safety Data Favorable risk/benefit profile in this study AEs mostly related to SC injection Drug-related ISRs in 3/16 participants ALT elevations <2.5 ULN; both participants started study with elevated ALT One SAE of nephrolithiasis No other clinically significant laboratory abnormali

  59. Slide 59: Nedosiran Clinical Trial Program to NDA Filing

    Nedosiran Clinical Trial Program to NDA Filing Coordinated Program of Clinical Trials to Support a Broad Label in PH Trial Description/Details Status PH Type Study 201: Pivotal, double-blind, randomized, placebo-controlled trial (2:1 randomization) Monthly fixed-dose, enabling prefilled syringes at

  60. Slide 60: Nedosiran Summary

    Nedosiran Summary PHYOX3 Day 120 results in line with expectations from single-dose PHYOX1 study Already a high percentage of participants with normalization/near-normalization at Day 120 High Uox percent reduction despite low baseline Average Uox for PH1 participants at Day 120 was in the normal ra

  61. Slide 61: Our Investigators & Site Teams

    Our Investigators & Site Teams Screening and Enrolling Participants

  62. Slide 62: Nedosiran Business Planning

    Nedosiran Business Planning Rob Ciappenelli Chief Commercial Officer

  63. Slide 63: Nedosiran: The Only RNAi Drug Candidate in Development for All PH Types

    Nedosiran: The Only RNAi Drug Candidate in Development for All PH Types Limited Disease Awareness, Education and Resources to Efficiently Diagnose PH Nedosiran’s target profile provides a comprehensive treatment option for all PH patients with convenient once monthly dosing, including self administr

  64. Slide 64: Milestones Projected Over Next Two Years

    Multiple Important Clinical, Regulatory and Infrastructure Milestones Projected Over Next Two Years 2020 2021 2022 Launch Readiness Preparations Stand Up Commercial Build Enterprise Infrastructure PHYOX Clinical Trial Results Expected Establish Medical Group Target Regulatory Filings Potential Appro

  65. Slide 65: Establishing Product Strategy and Business Infrastructure

    Establishing Product Strategy and Business Infrastructure to Drive Nedosiran Global Commercialization U.S. Launch Readiness Outside the U.S. Launch Preparations Teams / Infrastructure: Commercial: Patient Advocacy, Patient Services, Marketing, Market Access, Insights/Analytics and Commercial Operati

  66. Slide 66: Nedosiran: Setting the Stage for Commercial Success

    Nedosiran: Setting the Stage for Commercial Success Nedosiran has potential to address all patients with PH, regardless of type Mechanism: Nedosiran silences LDHA, the ultimate step in the oxalate production pathway Development Plan: Comprehensive PHYOX development program to evaluate all types of P

  67. Slide 67: Extrahepatic Platform

    Extrahepatic Platform Bob D. Brown, Ph.D. Chief Scientific Officer, Executive Vice President Research & Development

  68. Slide 68: Platform Expansion to Achieve Effective Extrahepatic Delivery

    Platform Expansion to Achieve Effective Extrahepatic Delivery Including Central and Peripheral Nervous Tissues and Other Extrahepatic Tissues Novel nucleic acid constructs with variable secondary structures and chemical compositions ± Non-GalNAc ligands (e.g. small molecules, peptides, Fabs, etc.) 1

  69. Slide 69: Accessing Multiple Cell Types in the Central Nervous System

    Accessing Multiple Cell Types: Delivery to Neurons, Astrocytes and Oligodendrocytes in the Central Nervous System Many neurological disorders are not cell type specific, highlighting the need for a platform that enables delivery and potency in a variety of cell types Modified siRNA payloads have bee

  70. Slide 70: Medchem/SAR Activity in Mouse CNS After Intrathecal Administration

    Medchem/SAR Activity in Mouse CNS After Intrathecal Administration One 300 µg Dose (≈10 mg/kg equivalent), Target Knockdown at Day 7 vs. Day 28 CNS Target Knockdown at Day 28 CNS Target Knockdown at Day 7 % Target mRNA Remaining [Target mRNA/Ppib mRNA]±SEM % Target mRNA Remaining [Target mRNA/Ppib m

  71. Slide 71: Delivery via I.T. versus I.C.M. Administration in Rats

    Delivery of Novel Constructs via I.T. versus I.C.M. Administration in Rats Yields Consistent CNS-Wide Target mRNA Knockdown Efficient mRNA Target Reduction Independent of Route of Administration Intrathecal Lumbar vs. Intrathecal Cisterna Magna Administration of in Rats % Target mRNA Remaining [Targ

  72. Slide 72: CNS Tissue Distribution After Intracisternal and Intrathecal Administration

    CNS Tissue Distribution After Intracisternal and Intrathecal Administration Bulk Distribution of RNAi Payload Throughout Rat CNS by in situ Hybridization (ISH) Detection aCSF, brain i.c.m., brain i.t., brain aCSF, spinal cord i.c.m., spinal cord i.t. , spinal cord RNAi Test Article Exposure by ISH (

  73. Slide 73: Durable CNS Target mRNA Knockdown After a Single Dose in Rats

    Durable CNS Target mRNA Knockdown After a Single Dose in Rats 1 mg Dose, i.t. Time (Days) Ongoing mRNA Reduction 160 Days After a Single Lumbar Intrathecal Dose % Target mRNA Remaining [Target mRNA/Ppib mRNA]±SEM Sustained control of target mRNA reduction for at least 160 days (ongoing) The duration

  74. Slide 74: Widespread Target mRNA Reduction in Nonhuman Primate CNS

    Widespread Therapeutic Target mRNA Reduction in Nonhuman Primate (NHP) CNS by RNAi in the Absence of Complex Conjugation Broad Distribution and Target mRNA Reduction 28 Days After a Single 45 mg i.c.m. Dose Target mRNA Reduction Throughout Primate CNS at Day 28 % Target mRNA Remaining [Target mRNA/(

  75. Slide 75: Cellular Uptake in NHP CNS After Intracisternal Administration

    Cellular Uptake in NHP CNS After Intracisternal Administration High Resolution Images Reveal Delivery and Intracellular Accumulation in Multiple Cell Types In situ hybridization (ISH) visualization of test article at 20x magnification RT-PCR of target mRNAs confirms intracellular delivery and target

  76. Slide 76: New Indications Enabled by Delivery To Extrahepatic Non-Neural Tissues

    New Indications Are Enabled by Delivery To Extrahepatic Non-Neural Tissues Using Nucleic Acid Platforms Without GalNAc Optimized chemistries enables delivery to multiple tissues beyond the liver Delivery to multiple tissues expands the range of important cardiovascular and metabolic targets to acces

  77. Slide 77: Flexible Subcutaneous Dosing Regimens Yield Equivalent Knockdown

    Flexible Subcutaneous Dosing Regimens Yield Equivalent Extrahepatic Target Knockdown Multiple effective dosing regimens support flexible subcutaneous clinical development strategies Mice, 15 mg/kg Total Exposure, Subcutaneous Administration Skeletal Muscle Adipose % Target mRNA Remaining (rel to PBS

  78. Slide 78: Rodents Are Predictive of Extrahepatic Activity in NHPs

    Rodents Are Predictive of Extrahepatic Activity in NHPs SAR and medchem screening in rodents enables rapid, reliable translation into monkeys Mouse Sampled at Two Weeks; NHP Samples at Four Weeks Skeletal Muscle Monkey, Week 4 Mouse, Week 2 Adipose Monkey, Week 4 Mouse, Week 2 % Target mRNA Remainin

  79. Slide 79: Broadly Distributed Activity in Individual Tissue Types in Nonhuman Primates

    Broadly Distributed Activity Is Observed Within Individual Tissue Types in Nonhuman Primates Target mRNA Measured 4 Weeks After a Single Subcutaneous Dose Soleus Gastrocnemius Bicep Tricep Skeletal Muscles Adipose Tissues Gonadal Subcutaneous Mesenteric Up to 85% target reduction detected in both pe

  80. Slide 80: Expansion of Dicerna's Therapeutic Nucleic Acid Platforms and Programs

    Expansion of Dicerna’s Therapeutic Nucleic Acid Platforms and Programs We are developing nucleic acid technologies independent of the hepatic GalNAc/ASGPR system Chemical and structural modifications of our clinical-stage GalXC platform have: Increased the intrinsic drug-like properties of our RNAi

  81. Slide 81: Closing Remarks

    Closing Remarks Douglas M. Fambrough, Ph.D., President and Chief Executive Officer

  82. Slide 82: Dicerna: Well Positioned for Near- and Long-Term Success

    Dicerna: Well Positioned for Near- and Long-Term Success Core pipeline of early and late-stage assets with multiple development milestones over next year+ Nedosiran: A potential best-in-class therapeutic for PH1, PH2 and PH3 RG6346: A Potential best-in-class therapeutic for the treatment of chronic

  83. Slide 83: Q&A Dicerna Management Team

    Q&A Dicerna Management Team

Dicerna Pharmaceuticals — Technical Presentation (August 2020) on 6ix